兴齐眼药(300573.SZ)：环孢素滴眼液(Ⅱ)上市后临床试验取得Ⅳ期临床研究报告

智通财经11-12

智通财经APP讯，兴齐眼药(300573.SZ)发布公告，公司的产品环孢素滴眼液(Ⅱ)，近期获得了“环孢素滴眼液(Ⅱ)治疗干眼的安全性和有效性多中心临床研究”的Ⅳ期临床研究报告。已经获得批准的适应症：本品可促进干眼症患者的泪液分泌，适用于与角结膜干燥症相关的眼部炎症所导致的泪液生成减少的患者。该研究是一项多中心、前瞻性临床试验，1999例受试者经过了为期24周的用药观察，评价环孢素滴眼液(Ⅱ)用于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482268927?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-12 15:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482268927","market":"hk","top_or_hot":-1,"title":"兴齐眼药(300573.SZ)：环孢素滴眼液(Ⅱ)上市后临床试验取得Ⅳ期临床研究报告","media":"智通财经","content":"<div>\n<p>智通财经APP讯，兴齐眼药(300573.SZ)发布公告，公司的产品环孢素滴眼液(Ⅱ)，近期获得了“环孢素滴眼液(Ⅱ)治疗干眼的安全性和有效性多中心临床研究”的Ⅳ期临床研究报告。已经获得批准的适应症：本品可促进干眼症患者的泪液分泌，适用于与角结膜干燥症相关的眼部炎症所导致的泪液生成减少的患者。该研究是一项多中心、前瞻性临床试验，1999例受试者经过了为期24周的用药观察，评价环孢素滴眼液(Ⅱ)用于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1209755.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>兴齐眼药(300573.SZ)：环孢素滴眼液(Ⅱ)上市后临床试验取得Ⅳ期临床研究报告</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n兴齐眼药(300573.SZ)：环孢素滴眼液(Ⅱ)上市后临床试验取得Ⅳ期临床研究报告\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 15:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1209755.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，兴齐眼药(300573.SZ)发布公告，公司的产品环孢素滴眼液(Ⅱ)，近期获得了“环孢素滴眼液(Ⅱ)治疗干眼的安全性和有效性多中心临床研究”的Ⅳ期临床研究报告。已经获得批准的适应症：本品可促进干眼症患者的泪液分泌，适用于与角结膜干燥症相关的眼部炎症所导致的泪液生成减少的患者。该研究是一项多中心、前瞻性临床试验，1999例受试者经过了为期24周的用药观察，评价环孢素滴眼液(Ⅱ)用于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1209755.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1209755.html","article_id":"2482268927","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482268927","pubTimestamp":1731397454,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，兴齐眼药 发布公告，公司的产品环孢素滴眼液(Ⅱ)，近期获得了“环孢素滴眼液(Ⅱ)治疗干眼的安全性和有效性多中心临床研究”的Ⅳ期临床研究报告。该研究是一项多中心、前瞻性临床试验，1999例受试者经过了为期24周的用药观察，评价环孢素滴眼液(Ⅱ)用于干眼患者的安全性和有效性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300573":"兴齐眼药","BK1583":"高瓴概念","BK1576":"医药外包概念","BK0239":"医药制造","03347":"泰格医药","BK1141":"生命科学工具和服务","BK0177":"最小市值"},"translate_title":"Xingqi Eye Medicine (300573. SZ): Cyclosporine Eye Drops (II) post-marketing clinical trial obtained phase IV clinical research report","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300573":1,"03347":1},"content_text":"智通财经APP讯，兴齐眼药(300573.SZ)发布公告，公司的产品环孢素滴眼液(Ⅱ)，近期获得了“环孢素滴眼液(Ⅱ)治疗干眼的安全性和有效性多中心临床研究”的Ⅳ期临床研究报告。已经获得批准的适应症：本品可促进干眼症患者的泪液分泌，适用于与角结膜干燥症相关的眼部炎症所导致的泪液生成减少的患者。该研究是一项多中心、前瞻性临床试验，1999例受试者经过了为期24周的用药观察，评价环孢素滴眼液(Ⅱ)用于干眼患者的安全性和有效性。研究结果显示，环孢素滴眼液(II)总体安全性良好，耐受性好，同时可以有效改善干眼症状及体征。公司0.05%环孢素滴眼液(Ⅱ)已于2020年6月获批上市，2021年12月3日被纳入国家医保目录，本次开展的临床试验旨在进一步评价0.05%环孢素滴眼液(Ⅱ)在中国干眼患者中应用的安全性和有效性。本次获得Ⅳ期临床研究报告对公司近期业绩不会产生重大影响。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482268927"}